Allogeneic Transplantation
Myelodysplastic Syndrome Trials (MDS & CMML)
COMIRB:25-1655
Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)
PI: Maria Amaya
Eligibility criteria are described in the link below.
COMIRB: 25-1397
RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia (PI: McMahon, Brandon/25-1397)
PI: Brandon McMahon
Eligibility criteria are described in the link below.
COMIRB: 25-2789
A Phase 1 Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti- Leukemia or anti-MDS Activity of RPT1G in Patients with Acute Myeloid Leukemia (AML) and Higher-Risk (HR) Myelodysplastic Syndromes/Neoplasms (MDS)
PI: Dan Pollyea
Eligibility criteria are described in the link below.
COMIRB:26-0427
A Global Multicenter, Double-Blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination with Azacitidine (AZA) in Patients with Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4)
PI: Andrew Kent
Eligibility criteria are described in the link below.
Request an Appointment
If you would like to schedule an appointment, please give us a call.
Our intake coordinator will help you navigate the process of becoming a new patient including helping you obtain the necessary referrals, get the necessary medical records transferred, and coordinate care with your existing physicians. We are available to answer your questions about our clinic, your treatment, and participation in ongoing clinical trials.